Bright Minds Biosciences announced that it has received a letter from the Nasdaq, stating that following the resignation of Dr. Williamson from the company’s board of directors and audit committee, the Company no longer complies with Nasdaq’s independent director and audit committee requirements as set forth in Listing Rule 5605.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DRUG:
- Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
- Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
- Bright Minds Biosciences receives Nasdaq bid price notification
- Bright Minds Biosciences Announces Resignation of Board Member
